Cellerant Awarded SBIR Contract Funding to Develop CLT-009 for Treatment of Thrombocytopenia
October 8, 2012 - (Cellerant) - "Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase 1 contract and a Phase 2 option from the National Cancer Institute (NCI) valued up to $1,683,503." Read Full Article
